Quest Diagnostics Trading Volume Plummets 34.76% to 447th Position

On April 25, 2025, Quest Diagnostics (DGX) experienced a significant decline in trading volume, with a total of 1.80 billion shares traded, marking a 34.76% decrease from the previous day. This decline placed Quest Diagnostics at the 447th position in terms of trading volume for the day. The stock price of Quest Diagnostics also decreased by 1.20%.

During the Q1 2025 earnings call, Quest Diagnostics addressed several key issues, including the impact of tariffs on supply costs, gain share contracts, and payer dynamics. The company reported strong revenue growth, with revenue reaching $2.65 billion, a 12.1% increase year-over-year. This growth was driven by contributions from acquisitions, demand for advanced diagnostics, and expanded health plan access, as well as improved operational efficiency through automation and robotics.

Quest Diagnostics welcomed the court decision to vacate the FDA rule on lab developed tests, which would have required them to comply with additional regulatory costs. This decision ensures that patients and providers can continue to access innovative testing services without added regulatory costs. Organic volume increased by 2.4%, with reported volume down 0.9%, correcting for weather and leap-year impacts. This aligns with 2024 Q3 and Q4 trends. Growth was supported by large enterprise partnerships, such as being selected for the Optum Health preferred lab network, and demand from functional medicine providers.

Quest Diagnostics is targeting 3% annual cost savings and productivity improvements through Invigorate, automating various lab processes like tuberculosis testing and cervical cancer screening. These investments aim to enhance quality, customer experiences, and productivity across the business.